Adding TAR-200 to neoadjuvant cetrelimab improved the pCR rate in patients with muscle-invasive bladder cancer in a phase 2 trial.

A new treatment for advanced bladder cancer which doubles survival time has been approved for NHS use. The treatment for advanced bladder cancer had not significantly changed since the 1980s. Now, ...

UCSF researchers designed a CAR T-cell therapy and combined it with an older class of diabetes drugs called ...

The FDA has approved a gemcitabine intravesical system for Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive ...

The FDA has signed off on Johnson & Johnson’s highly anticipated bladder cancer drug Inlexzo, marking an advance in the ability to care for patients who otherwise face bladder removal and limit | The ...

In the absence of large RCTs comparing TMT versus RC for MIBC, investigators conducted a systematic review and meta-analysis.

Urothelial carcinoma (UC) is the second most common genitourinary cancer, leading to over 16,000 deaths a year in the U.S. Despite recent advances, the five-year survival rate for metastatic UC ...

Pfizer Inc. (NYSE:PFE) is one of the best dividend stocks to buy. On August 12, Pfizer and Astellas Pharma reported that ...

Adjuvant therapy with nivolumab (Opdivo, “nivo”) continues to show disease-free survival (DFS) and overall survival (OS) benefits compared with placebo among patients with muscle-invasive bladder ...

Urothelial carcinoma (UC) is the second most common genitourinary cancer, leading to over 16,000 deaths a year in the United ...

PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care (surgical cystectomy) in cisplatin-ineligible patients with muscle-invasive bladder ...

Tumors with higher stromal content may have a TME in an immune-overstimulated state, which could be a factor in their worse prognosis, the researchers suggested. Based on its associations with PD-L1 ...